Antisense oligonucleotides (ASOs) are a relatively new therapeutic entity that utilizes short chemically modified strands of DNA in targeted interactions with RNA to modulate the type or amount of resultant protein. This brief review summarizes the preclinical, translational, and early clinical development of an ASO designed to reduce the production of the disease-causing protein in Huntington's disease, an inherited neurodegenerative disease.
DandapaniS., RosseG., SouthallN., SalvinoJ.M., and ThomasC.J. (2012). Selecting, acquiring, and using small molecule libraries for high-throughput screening. Curr Protoc Chem Biol, 4, 177–191.
5.
KeiserM.S., KordasiewiczH.B., and McBrideJ.L. (2016). Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet, 25(R1), R53–R64.
6.
KordasiewiczH.B., StanekL.M., WancewiczE.V., MazurC., McAlonisM.M., PytelK.A., et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74, 1031–1044.
7.
MillerT., CudkowiczM., ShawP.J., GrahamD., FraddetteS., HoushyarH., et al. (2019). Safety, PK, PD, and exploratory efficacy in single and multiple dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS. Presented at: 2019 American Academy of Neurology Annual Meeting, May. 4–10, 2019; Philadelphia, PA (Abstract).
8.
SouthwellA.L., KordasiewiczH.B., LangbehnD., SkotteN.H., ParsonsM.P., VillanuevaE.B., et al. (2018). Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Sci Transl Med, 10, pii: eaar3959.
9.
StanekL.M., YangW., AngusS., SardiP.S., HaydenM.R., HungG.H., et al. (2013). Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. J Huntingtons Dis, 2, 217–228.
10.
TabriziS.J., LeavittB.R., LandwehrmeyerG.B., WildE.J., SaftC., BarkerR.A., et al. (2019). Targeting huntingtin expression in patients with Huntington's disease. N Engl J Med, 380, 2307–2316.
